Catherine Mackey - GW Pharmaceuticals Non-Executive Independent Director

<div class='circular--portrait' style='background:#FF6600;color: #f7f7f7;font-size:4em;padding-top: 25px;;'>GP</div>
GWPH -- USA Stock  

USD 128.11  0.89  0.69%

  Director
Dr. Catherine J. Mackey is NonExecutive Independent Director of the Company. Dr. Mackey is an experienced corporate executive, director and advisor with over thirty years of accomplishment in the biotechnology, pharmaceutical, and agricultural industries. She is currently Chief Executive Officer of CYPrus Therapeutics, Inc. and Chairman of the Board of Cour Pharmaceutical Development. In addition, she serves on the Board of Directors of Rady Children Hospital and as an advisor to several companies. Dr. Mackey previously served as Senior Vice President of Pfizer Worldwide RD and Director, of Pfizer La Jolla Laboratories, where she built Pfizer La Jolla into one of Pfizer main pharmaceutical research and development sites with over 1000 employees and a robust drug pipeline. Prior to that role she served as head of Strategic Alliances and also Genomic and Proteomic Sciences for Pfizer. Dr. Mackey spent the first part of her career in agricultural biotechnology, including as Vice President of DEKALB Genetics, Inc
Age: 60  Director Since 2017  Ph.D    
(44) 1223 235667  www.gwpharm.com
Mackey received her B.S. and Ph.D. degrees in microbiology and genetics from Cornell University.

Catherine Mackey Latest Insider Activity

Catherine Mackey over six months ago via Macroaxis 
GW Pharmaceuticals exotic insider transaction detected

GW Pharmaceuticals Management Efficiency

GW Pharmaceuticals Plc has return on total asset (ROA) of (5.79) % which means that it has lost $5.79 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 4.88 %, meaning that it created $4.88 on every $100 dollars invested by stockholders. GW Pharmaceuticals management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current Return on Investment is estimated to decrease to -17.2. The current Return on Average Assets is estimated to decrease to -0.01GW Pharmaceuticals Revenue to Assets are most likely to slightly decrease in the upcoming years. The last year's value of Revenue to Assets was reported at 0.0101. The current Total Assets Per Share is estimated to increase to 2.01, while Total Assets are estimated to decrease to roughly 884.4 M. The current Tax Liabilities is estimated to increase to about 619.8 K, while Total Liabilities is estimated to decrease to roughly 151.2 M.
The company currently holds 40.28 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. GW Pharmaceuticals Plc has a current ratio of 6.37, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Deborah DiSanzoAstrazeneca PLC
2017
Jacqueline BartonGilead Sciences
2018
Sherilyn McCoyAstrazeneca PLC
2017
Thomas GlocerMerck Company
2007
Craig ThompsonMerck Company
2008
Scott DavisJohnson Johnson
2016
David HooverEli Lilly And
2009
Per WoldOlsenGilead Sciences
2010
Edgar JannottaGrifols S A
2006
Weiying WangAstrazeneca PLC
2019
Robert BertoliniBristol Myers Squibb
2017
Jose GrasGrifols S A
2000
Robert KidderMerck Company
2005
Dinesh PaliwalBristol Myers Squibb
2013
Deryck MaughanGlaxoSmithKline PLC
2013
Anna LluchGrifols S A
2008
Andreas PlantaNovartis AG
2006
Peter WendellMerck Company
2003
Graham ChipchaseAstrazeneca PLC
2019
Luis BobadillaGrifols S A
2011
William HarrisonMerck Company
2009

Company Summary

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom. GW Pharmaceuticals operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 901 people.GW Pharmaceuticals Plc (GWPH) is traded on BATS Exchange in USA. It is located in Sovereign House Vision Park, Chivers Way Histon, Cambridge CB24 9BZ, United Kingdom and employs 901 people. GW Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

GW Pharmaceuticals Plc Leadership Team

William Waldegrave, Non-Executive Independent Director
Christopher Tovey, COO, Executive Director
Thomas Lynch, Non-Executive Independent Director
Catherine Mackey, Non-Executive Independent Director
Justin Gover, CEO, Director
Geoffrey Guy, Executive Chairman of the Board
James Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director
Julian Gangolli, Executive Director
Alicia Secor, Non-Executive Independent Director
Adam George, CFO, Company Secretary, Director
Cabot Brown, Non-Executive Independent Director
Stephen Wright, Research & Development Director, Executive Director
Darren Cline, Chief Commercial Officer, U.S.

Stock Performance Indicators

Current Sentiment - GWPH

GW Pharmaceuticals Plc Investor Sentiment

Most of Macroaxis users are currently bullish on GW Pharmaceuticals Plc. What is your judgment towards investing in GW Pharmaceuticals Plc? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Please also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page